Skip to main content
Clinical Trials/JPRN-UMIN000011152
JPRN-UMIN000011152
Recruiting
未知

Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomas - B-SRIM Study

B-SRIM Study Group0 sites38 target enrollmentJuly 11, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
B-SRIM Study Group
Enrollment
38
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 11, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
B-SRIM Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients who are pregnant or in the location period, and who are not able to, or not willing to prevent conception during the therapeutic period of this clinical study 2\. Patients who have coinciding active cancer 3\. Patients who have psychiatric disorder 4\. Patients who have circulating lymphoma cells \>\= 25,000 /uL in peripheral blood 5\. Patients who have interstitial pneumonia or pulmonary fibrosis 6\. Patients who have central nerve system lymphoma 7\. Patients who have severe allergic reaction to medication 8\. Patients who are considered as inappropriate to register by physician

Outcomes

Primary Outcomes

Not specified

Similar Trials